7 completed. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 7 |
Follow Enterocolitis, Pseudomembranous: new trials by email Literature Review of Enterocolitis, Pseudomembranous trials Research Report on Enterocolitis, Pseudomembranous
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection RBX2660 - Clostridium Difficile Infection Recurrence | Phase 3 | Completed | Ferring Pharmaceuticals | 41 | 2023-04-21 | 2026-04-24 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) RBX2660 - Clostridium Difficile Infection, Infection | Phase 3 | Completed | Rebiotix Inc. | 793 | 2019-07-30 | 2024-08-07 |
| Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence) - Clostridium Difficile Infection (CDI) | Phase 3 | Completed | Rebiotix Inc. | 320 | 2017-07-31 | 2024-07-10 |
| A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Tolevamer potassium-sodium (GT267-004) - Clostridium Enterocolitis, Diarrhea | Phase 3 | Completed | Genzyme, a Sanofi Company | 520 | 2005-04-01 | 2014-03-19 |
| A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea tolevamer potassium-sodium (GT267-004) - Clostridium Enterocolitis, Pseudomembranous Colitis | Phase 3 | Completed | Genzyme, a Sanofi Company | 520 | 2005-03-01 | 2015-03-05 |
| Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment Metronidazole and Rifampin - Clostridium Enterocolitis, Antibiotic-Associated Diarrhea | Phase 3 | Completed | McMaster University | 100 | 2004-02-01 | 2018-08-15 |
| Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Nitazoxanide - Clostridium Enterocolitis, Pseudomembranous Colitis | Phase 3 | Completed | Daniel M. Musher MD | 22 | 2004-01-01 | 2017-12-15 |
Diarrhea (4) · Clostridium Infections (2) · Communicable Diseases (1) · Infections (1)
Bacterial Infections (7) · Bacterial Infections and Mycoses (7) · Digestive System Diseases (7) · Enterocolitis (7) · Gastroenteritis (7) · Gastrointestinal Diseases (7) · Gram-Positive Bacterial Infections (7) · Intestinal Diseases (7) · Infections (6) · Clostridium Infections (5) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Signs and Symptoms, Digestive (4) · Disease Attributes (1) · Pathologic Processes (1)
Metronidazole (1) · Rifampin (1) · Saline Solution (1) · Single Person (1) · nitazoxanide (1)
Genzyme, a Sanofi Company (2) · Rebiotix Inc. (2) · Daniel M. Musher MD (1) · Ferring Pharmaceuticals (1) · McMaster University (1)
United States (5) · Canada (4) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Ireland (1) · Norway (1) · Portugal (1) · Puerto Rico (1) · Spain (1) · Sweden (1)
Teena Chopra, M.D., M.P.H. (2) · Christine H Lee, MD (1) · Daniel M Musher, M.D. (1)
PMID 42286373, PMID 24799326, PMID 41245385, PMID 36287379, PMID 37564743, PMID 38236515, PMID 39172632, PMID 39180326, PMID 40177588, PMID 40321366, PMID 40552763, PMID 40672762, PMID 40784972, PMID 41115624, PMID 41230019, PMID 41647268, PMID 41653256, PMID 42840322